Form 4 for INSM INSMED Inc
Accepted 2025-01-10 00:00:00 ET · period of report 2025-01-07 · accession 0001628280-25-001204 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-10 | 2025-01-07 | INSM | Wise John Drayton | Chief Commercial Off | M - OptEx | $16.07 | +10.0K | 132.5K | +8% | +$160.7K |
| DM | 2025-01-10 | 2025-01-07+ | INSM | Wise John Drayton | Chief Commercial Off | S - Sale+OE | $65.95 | -13.6K | 119.6K | -10% | -$896.1K |
| D | 2025-01-10 | 2025-01-08 | INSM | Wise John Drayton | Chief Commercial Off | A - Grant | — | +6,657 | 125.8K | +6% | — |
| D | 2025-01-10 | 2025-01-07 | INSM | Wise John Drayton | Chief Commercial Off | M - OptEx | $0.00 | -10.0K | 0 | -100% | $0 |
| D | 2025-01-10 | 2025-01-08 | INSM | Wise John Drayton | Chief Commercial Off | A - Grant | $0.00 | +31.9K | 31.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-07 | M | A | 10,000 | $16.07 | 132,492 | D | — | — | (F2) Includes 835 shares acquired through the Company's 2018 Employee Stock Purchase Plan. |
| 2 | Common | Common Stock | 2025-01-07 | S | D | 10,000 | $65.98 | 122,492 | D | — | — | |
| 3 | Common | Common Stock | 2025-01-10 | S | D | 287 | $65.40 | 125,562 | D | — | — | |
| 4 | Common | Common Stock | 2025-01-08 | S | D | 392 | $66.21 | 119,192 | D | — | — | |
| 5 | Common | Common Stock | 2025-01-08 | A | A | 6,657 | — | 125,849 | D | — | — | (F5) Represents RSUs, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested. (F6) Each RSU was granted on January 8, 2025 for no consideration. |
| 6 | Common | Common Stock | 2025-01-07 | S | D | 2,908 | $65.87 | 119,584 | D | — | — | (F4) This is the weighted average sales price representing 2,908 shares sold at prices ranging from $65.84 to $65.93 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 7 | Derivative | Stock Option (right to buy) | 2025-01-07 | M | D | 10,000 | $0.00 | 0 | D | $16.07 · — to 2025-01-08 | 10,000 Common Stock | (F7) The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. |
| 8 | Derivative | Stock Option (right to buy) | 2025-01-08 | A | A | 31,930 | $0.00 | 31,930 | D | $65.72 · — to 2035-01-08 | 31,930 Common Stock | (F8) These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested. |